Cargando…
The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C
Hepatitis C virus (HCV) affects approximately 268,000 Canadians and results in more years of life lost than any other infectious disease in the country. Both the Canadian Institutes of Health Research (CIHR) and the Public Health Agency of Canada (PHAC) have identified HCV-related liver disease as a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098058/ https://www.ncbi.nlm.nih.gov/pubmed/27843889 http://dx.doi.org/10.1155/2016/7603526 |
_version_ | 1782465706768465920 |
---|---|
author | van Buuren, Nicholas Fradette, Lorraine Grebely, Jason King, Alexandra Krajden, Mel MacParland, Sonya A. Marshall, Alison Saeed, Sahar Wilson, Joyce Klein, Marina B. Sagan, Selena M. |
author_facet | van Buuren, Nicholas Fradette, Lorraine Grebely, Jason King, Alexandra Krajden, Mel MacParland, Sonya A. Marshall, Alison Saeed, Sahar Wilson, Joyce Klein, Marina B. Sagan, Selena M. |
author_sort | van Buuren, Nicholas |
collection | PubMed |
description | Hepatitis C virus (HCV) affects approximately 268,000 Canadians and results in more years of life lost than any other infectious disease in the country. Both the Canadian Institutes of Health Research (CIHR) and the Public Health Agency of Canada (PHAC) have identified HCV-related liver disease as a priority and supported the establishment of a National Hepatitis C Research Network. In 2015, the introduction of new interferon- (IFN-) free therapies with high cure rates (>90%) and few side effects revolutionized HCV therapy. However, a considerable proportion of the population remains undiagnosed and treatment uptake remains low in Canada due to financial, geographical, cultural, and social barriers. Comprehensive prevention strategies, including enhanced harm reduction, broader screening, widespread treatment, and vaccine development, are far from being realized. The theme of the 2016 symposium, “We're not done yet: remaining challenges in Hepatitis C,” was focused on identifying strategies to enhance prevention, diagnosis, and treatment of HCV to reduce disease burden and ultimately eliminate HCV in Canada. |
format | Online Article Text |
id | pubmed-5098058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-50980582016-11-14 The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C van Buuren, Nicholas Fradette, Lorraine Grebely, Jason King, Alexandra Krajden, Mel MacParland, Sonya A. Marshall, Alison Saeed, Sahar Wilson, Joyce Klein, Marina B. Sagan, Selena M. Can J Gastroenterol Hepatol Commentary Hepatitis C virus (HCV) affects approximately 268,000 Canadians and results in more years of life lost than any other infectious disease in the country. Both the Canadian Institutes of Health Research (CIHR) and the Public Health Agency of Canada (PHAC) have identified HCV-related liver disease as a priority and supported the establishment of a National Hepatitis C Research Network. In 2015, the introduction of new interferon- (IFN-) free therapies with high cure rates (>90%) and few side effects revolutionized HCV therapy. However, a considerable proportion of the population remains undiagnosed and treatment uptake remains low in Canada due to financial, geographical, cultural, and social barriers. Comprehensive prevention strategies, including enhanced harm reduction, broader screening, widespread treatment, and vaccine development, are far from being realized. The theme of the 2016 symposium, “We're not done yet: remaining challenges in Hepatitis C,” was focused on identifying strategies to enhance prevention, diagnosis, and treatment of HCV to reduce disease burden and ultimately eliminate HCV in Canada. Hindawi Publishing Corporation 2016 2016-10-24 /pmc/articles/PMC5098058/ /pubmed/27843889 http://dx.doi.org/10.1155/2016/7603526 Text en Copyright © 2016 Nicholas van Buuren et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary van Buuren, Nicholas Fradette, Lorraine Grebely, Jason King, Alexandra Krajden, Mel MacParland, Sonya A. Marshall, Alison Saeed, Sahar Wilson, Joyce Klein, Marina B. Sagan, Selena M. The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C |
title | The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C |
title_full | The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C |
title_fullStr | The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C |
title_full_unstemmed | The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C |
title_short | The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C |
title_sort | 5th canadian symposium on hepatitis c virus: we are not done yet—remaining challenges in hepatitis c |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098058/ https://www.ncbi.nlm.nih.gov/pubmed/27843889 http://dx.doi.org/10.1155/2016/7603526 |
work_keys_str_mv | AT vanbuurennicholas the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT fradettelorraine the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT grebelyjason the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT kingalexandra the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT krajdenmel the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT macparlandsonyaa the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT marshallalison the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT saeedsahar the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT wilsonjoyce the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT kleinmarinab the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT saganselenam the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT vanbuurennicholas 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT fradettelorraine 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT grebelyjason 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT kingalexandra 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT krajdenmel 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT macparlandsonyaa 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT marshallalison 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT saeedsahar 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT wilsonjoyce 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT kleinmarinab 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc AT saganselenam 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc |